The Ritedose Corporation
Ritedose Corporation is a US-based CDMO and generics manufacturer specializing in sterile Blow-Fill-Seal (BFS) technology, producing inhalation, ophthalmic, oral, and injectable unit-dose pharmaceuticals for large pharma, wholesalers, retail pharmacies, and hospitals.
- Company typePrivate
- Founded1995
- HeadquartersColumbia, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What The Ritedose Corporation does
The Ritedose Corporation is a privately held pharmaceutical CDMO and generics manufacturer founded in 1995 in Columbia, South Carolina, and acquired by Novo Holdings A/S (the holding company of the Novo Nordisk Foundation) in January 2022. The company specializes in Blow-Fill-Seal (BFS) aseptic manufacturing — an automated process that extrudes polymer into a mold, fills the formed container with product, and seals it in a continuous sterile operation — and is the largest US CDMO dedicated to sterile BFS technology, with current annual capacity of 1.8 billion doses and over 12 billion doses delivered since 2012 without patient interruption. Ritedose operates two business lines: (1) a CDMO division providing individualized contract development and manufacturing services for pharmaceutical clients from clinical trials through full-scale commercialization of ophthalmic, respiratory, and injectable medications; and (2) a generics division (Ritedose Pharmaceuticals) marketing its own portfolio of inhalation solutions, ophthalmic products, and oral liquids through wholesalers, major retail pharmacy chains, and hospitals. Ritedose commands over 45% of the US nebulized medication market and reports 100% customer retention over 25 years, with anchor clients including Viatris, Verona Pharma, Tenpoint Therapeutics, and a broad roster of global generics manufacturers.
The company runs on a B2B contract manufacturing and wholesale distribution model, with pricing not publicly disclosed and governed by multi-year contracts subject to price-list revision. It is currently executing an aggressive expansion: a 105-acre Ritedose Performance Park acquired in February 2024 with a $81M+ multi-year buildout, a seventh Syntegon packaging line doubling vial-processing capacity to 160-170 million units annually, a $17M cGMP laboratory expansion, and a 225,000 sq ft distribution and logistics center unveiled in June 2025. The workforce has scaled from 200+ to 600+ employees across recent years. The company has been awarded the SCbio 2026 Life Sciences Pinnacle Award and was recognized as the #1 American Heart Association Field Day company nationally in 2023. Ritedose operates exclusively within the United States and has no disclosed international footprint.
The Ritedose Corporation firmographics
Firmographics- Name
- The Ritedose Corporation
- Legal name
- The Ritedose Corporation
- Website
- https://ritedose.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Ritedose Corporation is a US-based CDMO and generics manufacturer specializing in sterile Blow-Fill-Seal (BFS) technology, producing inhalation, ophthalmic, oral, and injectable unit-dose pharmaceuticals for large pharma, wholesalers, retail pharmacies, and hospitals.
- Ownership category
- akta.pro rank
The Ritedose Corporation industry classification
Industry- Product category
- Sterile Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where The Ritedose Corporation is headquartered
LocationHeadquarters
- HQ city
- Columbia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
The Ritedose Corporation business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- CDMO Services: Contract development and manufacturing services for pharmaceutical companies from clinical trials through full-scale commercialization of ophthalmic, respiratory, and injectable medications using BFS technology.
- Generic Pharmaceuticals: Development and marketing of company's own portfolio of generic drugs including inhalation solutions, ophthalmic products, and oral liquids sold to wholesalers, retail pharmacies, and hospitals.
- 503B Outsourcing: Sterile compounding services for medically necessary drugs that are in short supply, supplying hospital pharmacies across the country.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Contract manufacturing pricing varies by product type, volume, and service requirements |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels4 records
The Ritedose Corporation product offering
Product offeringCore offering
The Ritedose Corporation is the largest U.S. Contract Development and Manufacturing Organization (CDMO) specializing in sterile Blow-Fill-Seal (BFS) technology, providing contract manufacturing services for pharmaceutical companies from clinical trials through full-scale commercialization. In parallel, the company operates a generics division (Ritedose Pharmaceuticals) that develops, manufactures, and markets its own portfolio of generic inhalation solutions, ophthalmic products, and oral liquids sold to wholesalers, retail pharmacy chains, and hospitals. Ritedose also developed the proprietary SuredoseRx single-dose liquid medication dispenser.
Product overview
The Ritedose Corporation is a CDMO and generics manufacturer specializing in sterile Blow-Fill-Seal (BFS) technology. The company operates two core divisions: (1) CDMO Services for contract development and manufacturing of sterile pharmaceuticals, and (2) a Generics division offering its own portfolio of generic medications. The BFS technology platform enables production of sterile unit-dose inhalation products, ophthalmic medications, oral liquids, and injectables. Key products include respiratory generics (Tobramycin, Albuterol, Formoterol, Arformoterol, Cromolyn Sodium), manufactured drug products (Yuvezzi for Tenpoint Therapeutics, Ohtuvayre for Verona Pharma), and the proprietary SuredoseRx™ liquid medication dispenser. Ritedose also previously operated a 503B outsourcing division for hospital compounding, though resources have since been pivoted to FDA-approved drug products. Products are available for wholesalers, retail pharmacy chains, and hospitals across the U.S.
Differentiator
Problem solved
Functional benefit
Products and services
- CDMO Services (Contract Development and Manufacturing)
- Generic Pharmaceuticals
- SuredoseRx Liquid Medication Dispenser
- Tobramycin Inhalation Solution
- Albuterol Sulfate Inhalation Solution
- Formoterol Fumarate Inhalation Solution
- Arformoterol Tartrate Inhalation Solution
- Cromolyn Sodium Inhalation Solution
- Cromolyn Sodium Oral Solution
- Atropine Sulfate Injection
- Ohtuvayre (ensifentrine)
- Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution)
- 503B Outsourcing Services
Quantifiable outcome
- 12+ billion doses delivered since 2012 with no patient interruptions
- +3 more outcomes
Companies that use The Ritedose Corporation
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
The Ritedose Corporation technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
The Ritedose Corporation partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, supporting and major.
- Tenpoint TherapeuticscoreRitedose selected as manufacturing partner for YUVEZZI (carbachol and brimonidine tartrate), the first and only FDA-approved dual-agent eye drop for treating presbyopia. Partnership positioned for commercial readiness and supply security for national launch.
- Syntegon TechnologycoreRitedose relies on Syntegon Technology for processing and packaging solutions. Added seventh Syntegon packaging line in 2025 to double capacity for individually wrapped vial medications, processing 160-170 million vials annually.
- Newberry CollegesupportingLaunched Pharmaceutical Manufacturing program starting summer 2025 - a 30-hour bachelor's program for students with associate degrees. 10 async courses focused on quality, compliance, and process optimization. First institution in SC to offer this specialized program.
- inSpringsupportingWorkforce development partnership to develop talent pipeline for first-gen and international candidates. Manages international worker visa process and provides workforce readiness training aligned with hiring needs.
- Benedict CollegesupportingHBCU partnership through RISE (Ritedose International Student Engagement) program - workforce initiative for international STEM students. Creates pipeline for laboratory positions at Ritedose.
- Verona PharmacoreRitedose serves as development and manufacturing partner for Ohtuvayre (ensifentrine), Verona Pharma's first-in-class COPD drug approved by FDA in June 2024. Ritedose manufactures national launch quantities for this groundbreaking respiratory therapy - the first inhaled product with a novel mechanism of action for COPD in over 20 years.
- Dispensary of HopemajorRitedose pledges long-term supply of critical respiratory medications for low-income and uninsured patients. Committed 1 million doses in 2024, building on 124,000 doses in 2023. Joined Hope Alliance campaign with other pharmaceutical companies including Viatris, Amneal, Aurobindo, and Hikma.
- ApiJectmajorSelected as subcontractor for production of single-dose prefilled syringes intended for administering COVID-19 vaccines. Repurposed and upgraded equipment to fill and finish up to 45 million prefilled syringes per month.
Scale indicators10 records
Recent moves12 records
Expansion highlights5 records
The Ritedose Corporation competitors and assessment
Company assessmentDirect peers
- Recipharm: Large European-based CDMO offering sterile fill-finish, inhalation, and injectables manufacturing across multiple dosage forms. Competes with Ritedose for ophthalmic, respiratory, and injectable CDMO contracts from pharma sponsors globally.
- Nephron Pharmaceuticals: South Carolina-based pharmaceutical manufacturer operating its own generics, contract manufacturing, and 503B outsourcing businesses. Directly competes with Ritedose in sterile inhalation solutions, ophthalmics, and BFS-adjacent formats, particularly for U.S. hospital and retail pharmacy customers.
- Gerresheimer AG: Global manufacturer of primary packaging and drug delivery systems including BFS-based sterile containers. Comparable to Ritedose in BFS technology depth and serves many of the same pharma CDMO customers for ophthalmic and respiratory unit-dose products.
- ApiJect: Single-dose prefilled syringe manufacturer built around aseptic BFS-style technology. Ritedose has been a subcontractor for ApiJect's COVID-19 syringe program, and the two compete for aseptic, single-dose, high-volume government and commercial contracts.
- Hovione: Contract development and manufacturing organization specializing in inhalation and sterile injectable drug products. Direct competitor to Ritedose in particle engineering and inhalation CDMO services for respiratory and ophthalmic indications.
Broad incumbents
- AptarGroup: Provider of drug delivery solutions, dispensing systems, and active material science serving pharmaceutical, beauty, and home markets. Aptar's Pharma segment offers inhalation, ophthalmic, and nasal delivery systems that overlap with Ritedose's device-plus-fill business (e.g., SuredoseRx).
- Catalent: One of the largest global CDMOs with a broad portfolio spanning softgels, biologics, sterile injectables, and inhalation. Overlaps with Ritedose in sterile fill-finish and inhalation CDMO services, but offers a much broader technology stack at significantly greater scale.
- Patheon (Thermo Fisher Scientific CDMO): Pharma services division of Thermo Fisher offering end-to-end drug development and commercial manufacturing. Competes with Ritedose for large pharma CDMO relationships across sterile and inhalation modalities.
- West Pharmaceutical Services: Global leader in primary packaging, elastomers, and drug delivery systems used by sterile injectable and inhalation drug manufacturers. Closely allied to — and competing for share of — Ritedose's CDMO and device-delivery customers.
Emerging players
- Curia (formerly AMRI): Integrated CDMO offering API development, sterile fill-finish, and drug product manufacturing across multiple modalities. An emerging competitor in sterile injectables and inhaled drug product CDMO spaces where Ritedose competes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
The Ritedose Corporation social profiles
Digital presenceThe Ritedose Corporation compliance and trust
Trust signalCompliance2 records
The Ritedose Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
The Ritedose Corporation leadership team
Management profileNumber of profiles
Profiles5 records
The Ritedose Corporation subsidiaries and ownership
Company hierarchySubsidiaries1 record
The Ritedose Corporation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The Ritedose Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The Ritedose Corporation
What does The Ritedose Corporation do?
The Ritedose Corporation is the largest U.S. Contract Development and Manufacturing Organization (CDMO) specializing in sterile Blow-Fill-Seal (BFS) technology, providing contract manufacturing services for pharmaceutical companies from clinical trials through full-scale commercialization. In parallel, the company operates a generics division (Ritedose Pharmaceuticals) that develops, manufactures, and markets its own portfolio of generic inhalation solutions, ophthalmic products, and oral liquids sold to wholesalers, retail pharmacy chains, and hospitals. Ritedose also developed the proprietary SuredoseRx single-dose liquid medication dispenser.
Is The Ritedose Corporation a public or private company?
The Ritedose Corporation is a private company. It is classified as corporate owned and is currently operating.
When was The Ritedose Corporation founded?
The Ritedose Corporation was founded in 1995. It employs 501 to 1,000 people.
Where is The Ritedose Corporation based?
The Ritedose Corporation is headquartered in Columbia, United States, in the North America region.
How does The Ritedose Corporation make money?
Three revenue lines are on record. CDMO Services are the primary driver. The others are generic Pharmaceuticals and 503B Outsourcing.
Who are The Ritedose Corporation's main competitors?
Direct peers on record are Recipharm, Nephron Pharmaceuticals, Gerresheimer AG, ApiJect and Hovione. Broad incumbents are AptarGroup, Catalent, Patheon (Thermo Fisher Scientific CDMO) and West Pharmaceutical Services. Curia (formerly AMRI) is listed as an emerging player.
Does The Ritedose Corporation have an API?
No public API is recorded for The Ritedose Corporation.
What industry is The Ritedose Corporation in?
The Ritedose Corporation's product category is Sterile Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.